{{Infobox medical condition (new)
| name = 發熱性非溶血性輸血反應
| image = 
| caption = 
| pronounce = 
| field = [[血液學|血液學]]
| synonyms = Febrile-type reaction
| symptoms = 
| complications = 
| onset = 
| duration = 4小時以內
| types = 
| causes = 
| risks = 
| diagnosis = 
| differential = 
| prevention = 使用減白血品
| treatment = 
| medication = [[对乙酰氨基酚|对乙酰氨基酚]]
| prognosis = 良好
| frequency = 約1-3%
| deaths = 
}}
'''發熱性非溶血性輸血反應'''（Febrile non-hemolytic transfusion reaction，FNHTR）是[[輸血反應|輸血反應]]中最常見的一種。在某些受血者在進行[[輸血|輸血]]時，會出現[[發燒|發燒]]但沒有[[溶血反應|溶血]]的情形<ref name="pmid10546797">{{cite journal |author=Heddle NM |title=Pathophysiology of febrile nonhemolytic transfusion reactions |journal=Curr. Opin. Hematol. |volume=6 |issue=6 |pages=420–6 |date=November 1999 |pmid=10546797 |doi= 10.1097/00062752-199911000-00012}}</ref>。目前認為一般是因受血者的抗體直接攻擊捐贈者的白血球所導致。此類情形常發生於多次受血者，如[[地中海型貧血|地中海型貧血]]病人等。FNHTR也可能由血漿中積累的細胞激素誘發，因此使用存放越久的血品，發生此情形的機會越高<ref name="Robbins2018">{{cite book|editor1-last=Kumar|editor1-first=Vinay|editor2-last=Abbas|editor2-first=Abul K.|editor3-last=Aster|editor3-first=Jon C.|title=Robbins Basic Pathology|date=28 March 2017|publisher=Elsevier|location=Philadelphia, Pennsylvania|isbn=978-0-323-35317-5|page=491|edition=Tenth}}</ref>。

== 診斷 ==
FNHTR的診斷必須先排除其他疾病，例如潛在的感染、血品細菌汙染，或其他輸血反應（如{{tsl|en|acute hemolytic transfusion reaction|急性溶血性輸血反應|}}）等<ref name=":0">{{Cite web|url=http://www.isbtweb.org/fileadmin/user_upload/Proposed_definitions_2011_surveillance_non_infectious_adverse_reactions_haemovigilance_incl_TRALI_correction_2013.pdf|title=Proposed standard definitions for surveillance of non infectious adverse transfusion reactions|last=|first=|date=|website=www.isbtweb.org|access-date=2019-01-09|archive-date=2020-11-28|archive-url=https://web.archive.org/web/20201128103302/http://www.isbtweb.org/fileadmin/user_upload/Proposed_definitions_2011_surveillance_non_infectious_adverse_reactions_haemovigilance_incl_TRALI_correction_2013.pdf|dead-url=no}}</ref>。典型症狀為發燒畏寒及寒顫<ref name=":0" />、且患者必須符合以下條件：

# [[發燒|發燒]]，口溫需達38<sup>o</sup>C以上，且跟輸血前比較必須高達1<sup>o</sup>C以上。
# 症狀在停止輸血後的4小時內緩解<ref name=":0">{{Cite web|url=http://www.isbtweb.org/fileadmin/user_upload/Proposed_definitions_2011_surveillance_non_infectious_adverse_reactions_haemovigilance_incl_TRALI_correction_2013.pdf|title=Proposed standard definitions for surveillance of non infectious adverse transfusion reactions|last=|first=|date=|website=www.isbtweb.org|access-date=2019-01-09}}</ref>

== 評估 ==
英國血液安全監視系統（{{tsl|en|Serious Hazards of Transfusion|輸血嚴重危害|SHOT}}）對於此反應的嚴重程度進行分級<ref name=":1">{{Cite web|title=2019 Annual SHOT Report – 16. Febrile, Allergic and Hypotensive Reactions (FAHR)|url=https://www.shotuk.org/wp-content/uploads/myimages/16.-Febrile-Allergic-and-Hypotensive-Reactions-FAHR-2.pdf|accessdate=|author=|date=|year=2020|format=|publisher=SHOT|language=|last1=Birchall|first1=Janet|last2=Peters|first2=Jayne|website=|access-date=|archive-date=2021-09-11|archive-url=https://web.archive.org/web/20210911090419/https://www.shotuk.org/wp-content/uploads/myimages/16.-Febrile-Allergic-and-Hypotensive-Reactions-FAHR-2.pdf|dead-url=no}}</ref>：

=== 輕度 ===
體溫達38<sup>o</sup>C以上，且體溫變化於1-2<sup>o</sup>C之間，除此之外沒有其他症狀<ref name=":1" />。

=== 中度 ===
體溫達39<sup>o</sup>C以上，或體溫變化達2<sup>o</sup>C以上。可能出現[[發冷|畏寒]]、[[肌肉痛|肌痛]]，或[[恶心|噁心]]等症狀，致使輸血必須立即中斷<ref name=":1" />。

=== 重度 ===
體溫達39<sup>o</sup>C以上，或體溫變化達2<sup>o</sup>C以上。可能出現[[發冷|畏寒]]、[[肌肉痛|肌痛]]，或[[恶心|噁心]]等症狀，致使輸血必須立即中斷。且需要緊急醫療處置、住院，或延長住院等<ref name=":1" />。

== 生理機轉 ==
目前認為通常是因為受血者的抗體直接攻擊血品中的白血球及和HLA抗原所致<ref name="First Aid 2017">{{cite book|last1=Le|first1=Tao|last2=Bhushan|first2=Vikas|last3=Sochat|first3=Matthew|last4=Chavda|first4=Yash|title=First Aid for the USMLE Step 1 2017: a Student-to-Student Guide|date=6 January 2017|publisher=McGraw Hill Education|isbn=978-1-25-983762-3|page=110|edition=27th}}</ref>。FNHTR與[[輸血相關急性肺損傷|輸血相關急性肺損傷]]（transfusion-associated acute lung injury，TRALI）的機制正好相反：前者是受血者的抗體攻擊血品中的白血球，而後者則是血品中的抗體活化受血者的白血球，進而引至肺部損傷。此外，除了抗體攻擊白血球這個機制之外，血品中的細胞激素也可能會引發FNHTR<ref name="pmid16764597">{{cite journal|title=The association of cytokine gene polymorphisms with febrile non-hemolytic transfusion reaction in multitransfused patients|date=June 2006|journal=Transfus Med|issue=3|doi=10.1111/j.1365-3148.2006.00665.x|volume=16|pages=184–91|pmid=16764597|vauthors=Addas-Carvalho M, Salles TS, Saad ST}}</ref><ref name="pmid14692961">{{cite journal|title=The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC|url=https://archive.org/details/sim_transfusion_2004-01_44_1/page/10|date=January 2004|journal=Transfusion|issue=1|doi=10.1046/j.0041-1132.2003.00518.x|volume=44|pages=10–5|pmid=14692961|vauthors=Yazer MH, Podlosky L, Clarke G, Nahirniak SM}}</ref>。由於血品中的白血球在儲放過程中可能裂解，會將細胞內的[[細胞激素|細胞激素]]釋放至血品血漿中，因此存放越久的血品細胞激素含量越高<ref name="First Aid 2020">{{cite book|last1=Le|first1=Tao|last2=Bhushan|first2=Vikas|last3=Sochat|first3=Matthew|last4=Vaidyanathan|first4=Vaishnavi|title=First Aid for the USMLE Step 1 2020: 30th Anniversary Edition|date=3 January 2020|publisher=McGraw Hill Education|isbn=978-1-26-046205-0|page=114|edition=30th Anniversary}}</ref>，引發FNHTR的機會也越高<ref name="Robbins2018" />。

== 處置及治療 ==
當FNHTR發生時，必須立即停止輸血，並鑑別患者是否具有溶血或感染的症狀。實驗室檢測可進行[[Direct_antiglobulin_test|抗人球蛋白測試]]，以檢測是否有發生溶血反應。可給予[[对乙酰氨基酚|对乙酰氨基酚]]進行治療，且日後若要輸血時建議使用減白血品<ref name=":2">{{Cite journal|title=Red blood cell transfusion in clinical practice|url=https://linkinghub.elsevier.com/retrieve/pii/S0140673607611970|last=Klein|first=Harvey G|last2=Spahn|first2=Donat R|date=2007-08|journal=The Lancet|issue=9585|doi=10.1016/S0140-6736(07)61197-0|volume=370|pages=415–426|language=en|last3=Carson|first3=Jeffrey L|access-date=2020-09-02|archive-date=2021-12-02|archive-url=https://web.archive.org/web/20211202090411/https://linkinghub.elsevier.com/retrieve/pii/S0140673607611970|dead-url=no}}</ref>。

若症狀疑似FNHTR，但體溫上升不到一度，也需暫停輸血，並持續監測病人的生命徵象。若監測一段時間後無其他症狀，可以斟酌恢復輸血<ref name=":3">{{Cite journal|title=Transfusion reactions: prevention, diagnosis, and treatment|url=https://pubmed.ncbi.nlm.nih.gov/27083327/|last=Delaney|first=Meghan|last2=Wendel|first2=Silvano|date=12 03, 2016|journal=Lancet (London, England)|issue=10061|doi=10.1016/S0140-6736(15)01313-6|volume=388|pages=2825–2836|issn=1474-547X|pmid=27083327|last3=Bercovitz|first3=Rachel S.|last4=Cid|first4=Joan|last5=Cohn|first5=Claudia|last6=Dunbar|first6=Nancy M.|last7=Apelseth|first7=Torunn O.|last8=Popovsky|first8=Mark|last9=Stanworth|first9=Simon J.|access-date=2020-09-02|archive-date=2020-11-06|archive-url=https://web.archive.org/web/20201106063947/https://pubmed.ncbi.nlm.nih.gov/27083327/|dead-url=no}}</ref>。

== 預防 ==
使用{{tsl|en|leukoreduction|減白血品|}}能夠有效預防FNHTR。雖然臨床上常在輸血前給予退燒藥，但實際上並不能減少FNHTR的發生率，因此不建議進行<ref name=":2" />。有部分證據顯示使用血小板添加液（platelet additive solutions）可以減少約0·17-0·5%的發生機率<ref name=":3" />。

==參考文獻==
{{reflist|2}}

== 外部連結 ==
{{Medical resources
|  DiseasesDB = 
|  ICD10 = {{ICD10|Y|44|6|y|40}}, {{ICD10|Y|44|7|y|40}}
|  ICD9 = 
|  ICDO = 
|  OMIM = 
|  MedlinePlus = 
|  eMedicineSubj = 
|  eMedicineTopic = Transfusion Medicine
|  MeshID = 
}}

[[Category:輸血反應|Category:輸血反應]]
[[Category:輸血醫學|Category:輸血醫學]]